buildleaf tirzepatide oral liquid Scam weight-loss drops marketed to Australians contain 'basically salty water', analysis finds | Scams tirzepatide buildleaf BuildLeaf™ Tirzepatide GLP-1

The 50 mg per-capsule format mirrors the daily oral dose used in published rodent pharmacology

Provider Assessment Framework: When to Defer or Avoid GLP-1 Therapy Qualified healthcare providers use structured clinical assessment to determine GLP-1 eligibility

Intestinal permeability in inflammatory bowel disease: Pathogenesis, clinical evaluation, and therapy of leaky gut

The FDA has issued guidance about compounded GLP-1 medications during shortage periods, generally supporting their use when brand options are unavailable

The evidence base here is built from mechanistic reasoning, metformin depletion data, and GLP-1 class effects, not from a head-to-head retatrutide-plus-B12 study